Global Fibrin Glue Market Strategic Outlook (2025–2036)
The global Fibrin Glue Market is positioned for significant growth as surgical procedures worldwide shift toward advanced biosurgical solutions for hemostasis and tissue sealing. Valued at USD XXXX Million in 2025, the market is projected to escalate to USD XXXX Million by 2036, growing at a compound annual growth rate (CAGR) of XX.X%. The rising volume of complex surgeries, coupled with a global emphasis on reducing post-operative complications, is driving the transition from traditional mechanical closures to biological adhesives.
Market Overview
Fibrin glue, a biological tissue adhesive consisting of fibrinogen and thrombin, mimics the final stage of the natural coagulation cascade. It has become an indispensable tool in modern surgery for its ability to achieve rapid hemostasis, seal tissues, and provide suture reinforcement. Unlike synthetic glues, fibrin-based products are fully biocompatible and biodegradable, making them the preferred choice for delicate procedures in neurosurgery, cardiovascular surgery, and organ transplants.
Market Segmentation
By Product Type
-
Liquid Fibrin Sealants: Primarily used for surface hemostasis and tissue sealing in general and specialized surgeries.
-
Fibrin Patches & Matrices: Collagen-based sponges impregnated with fibrinogen and thrombin, offering mechanical stability alongside biological sealing (e.g., TachoSil).
-
Autologous Fibrin Glue Kits: Systems that allow for the preparation of fibrin glue from the patient’s own blood, minimizing the risk of viral transmission or immunological reactions.
By Clinical Application
-
Cardiovascular Surgery: Suture line reinforcement and prevention of air leaks or bleeding in vascular grafts.
-
Neurosurgery: Dural sealing to prevent cerebrospinal fluid (CSF) leaks.
-
Orthopedic Surgery: Management of bleeding in total joint replacements and spinal fusions.
-
General Surgery: Spleen and liver trauma, as well as gastrointestinal anastomoses.
-
Wound Management: Treatment of chronic ulcers and burn grafts.
By End-User
-
Hospitals & Tertiary Care Centers: The primary volume drivers for high-stakes surgical procedures.
-
Ambulatory Surgical Centers (ASCs): A rapidly expanding segment due to the rise of minimally invasive outpatient surgeries.
-
Specialty Clinics: Focusing on plastic surgery and dental applications.
Regional Analysis
-
North America: Leads the market value due to advanced healthcare infrastructure, high surgical volumes, and the early adoption of high-cost biosurgical products in the United States and Canada.
-
Europe: A mature market driven by rigorous safety standards and a strong presence of key players in Germany, Switzerland, and the UK. Emphasis is placed on standardized clinical guidelines for blood-saving techniques.
-
Asia-Pacific: Anticipated to be the fastest-growing region. Growth is propelled by an aging population in Japan and China, a surge in medical tourism in Southeast Asia, and improving healthcare accessibility in India.
-
LAMEA (Latin America, Middle East, & Africa): Growth is emerging from the modernization of surgical suites in the GCC countries and the expansion of private healthcare networks in Brazil and Mexico.
Top Key Players
The landscape is dominated by diversified pharmaceutical giants and specialized biotechnology firms:
-
Baxter International Inc. (Tisseel, Artiss)
-
Ethicon, Inc. (Johnson & Johnson) (Evicel, Evarrest)
-
CSL Behring (CSL Limited)
-
Takeda Pharmaceutical Company Limited (TachoSil)
-
Mallinckrodt PLC
-
Vivostat A/S (Leader in autologous systems)
-
Regen Lab SA
-
Harvest Technologies (Terumo BCT)
-
Shanghai RAAS Blood Products Co., Ltd.
-
Kaketsuken (KM Biologics)
-
LifeBond Ltd.
-
Pharming Group N.V.
-
STB Lifesaving Technologies
-
Tissuemed Ltd.
Porter’s Five Forces Analysis
-
Bargaining Power of Buyers (High): Large hospital networks and Group Purchasing Organizations (GPOs) exert significant pressure on pricing and demand long-term clinical evidence for cost-benefit ratios.
-
Bargaining Power of Suppliers (Moderate): Suppliers of human plasma—the raw material for fibrinogen—hold moderate power due to the high costs of donor screening and fractionation.
-
Threat of New Entrants (Low): Barriers are extreme due to stringent FDA/EMA clinical trial requirements, complex manufacturing processes, and the need for high-purity biological components.
-
Threat of Substitutes (Moderate): Synthetic glues (cyanoacrylates) and mechanical closures (staples/sutures) are cheaper alternatives, though they lack fibrin’s biocompatibility.
-
Competitive Rivalry (Very High): Intense rivalry among top players to secure "first-line" status in surgical protocols and to innovate in room-temperature stable formulations.
SWOT Analysis
-
Strengths: Superior biocompatibility; effective in heparinized patients; minimizes surgical time.
-
Weaknesses: High cost per unit; limited shelf life and refrigeration requirements for many products.
-
Opportunities: Expansion into minimally invasive surgery (MIS); development of recombinant fibrin to eliminate human plasma risks.
-
Threats: Strict regulatory oversight; fluctuations in human plasma availability; price caps in emerging economies.
Trend Analysis
-
Transition to Recombinant Technology: Manufacturers are investing in recombinant DNA technology to produce fibrinogen and thrombin, reducing dependency on human blood donors and eliminating viral transmission risks.
-
Robotic Surgery Integration: Development of specialized applicators designed for robotic-assisted surgery platforms (e.g., Da Vinci systems).
-
Room-Temperature Stability: A shift toward products that do not require thawing or constant refrigeration, simplifying operating room logistics.
Drivers & Challenges
-
Drivers: Globally aging population requiring more complex surgeries; increasing prevalence of chronic diseases (cancer, cardiovascular issues); and a growing awareness of "bloodless surgery" techniques.
-
Challenges: The high technical barrier for high-yield fractionation; and the prohibitive cost of biologics in low-to-middle-income countries.
Value Chain Analysis
-
Plasma Sourcing: Procurement of human plasma through regulated donor centers.
-
Fractionation & Purification: Extracting fibrinogen and thrombin while ensuring viral inactivation.
-
Formulation: Developing delivery systems (dual-syringe applicators, spray tips).
-
Clinical Distribution: Cold-chain logistics to ensure biological activity is preserved during transport.
-
Surgical Application: Real-time mixing and application by specialized surgical staff.
Quick Recommendations for Stakeholders
-
For Manufacturers: Focus on Ready-to-Use (RTU) formulations. Operating room efficiency is a major hospital KPI; eliminating thawing time is a key competitive advantage.
-
For Investors: Target companies specializing in Autologous Fibrin Systems. These systems bypass donor-related viral risks and are gaining favor in specialized plastic and orthopedic surgery.
-
For Healthcare Providers: Implement Biosurgical Stewardship Programs to optimize the use of fibrin glue in high-risk patients, ensuring clinical benefits outweigh the high acquisition cost.
-
For R&D Teams: Invest in Recombinant Fibrin development to ensure long-term supply chain stability and compliance with evolving biosafety regulations.
1. Market Overview of Mastography
1.1 Mastography Market Overview
1.1.1 Mastography Product Scope
1.1.2 Market Status and Outlook
1.2 Mastography Market Size by Regions:
1.3 Mastography Historic Market Size by Regions
1.4 Mastography Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Mastography Sales Market by Type
2.1 Global Mastography Historic Market Size by Type
2.2 Global Mastography Forecasted Market Size by Type
2.3 Analog Mammography X-ray Unit
2.4 Digital Mammography X-ray Unit
3. Covid-19 Impact Mastography Sales Market by Application
3.1 Global Mastography Historic Market Size by Application
3.2 Global Mastography Forecasted Market Size by Application
3.3 Hospital
3.4 Other
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Mastography Production Capacity Market Share by Manufacturers
4.2 Global Mastography Revenue Market Share by Manufacturers
4.3 Global Mastography Average Price by Manufacturers
5. Company Profiles and Key Figures in Mastography Business
5.1 FUJIFILM Holdings
5.1.1 FUJIFILM Holdings Company Profile
5.1.2 FUJIFILM Holdings Mastography Product Specification
5.1.3 FUJIFILM Holdings Mastography Production Capacity, Revenue, Price and Gross Margin
5.2 GE
5.2.1 GE Company Profile
5.2.2 GE Mastography Product Specification
5.2.3 GE Mastography Production Capacity, Revenue, Price and Gross Margin
5.3 Hologic
5.3.1 Hologic Company Profile
5.3.2 Hologic Mastography Product Specification
5.3.3 Hologic Mastography Production Capacity, Revenue, Price and Gross Margin
5.4 Philips
5.4.1 Philips Company Profile
5.4.2 Philips Mastography Product Specification
5.4.3 Philips Mastography Production Capacity, Revenue, Price and Gross Margin
5.5 Siemens
5.5.1 Siemens Company Profile
5.5.2 Siemens Mastography Product Specification
5.5.3 Siemens Mastography Production Capacity, Revenue, Price and Gross Margin
5.6 ADANI
5.6.1 ADANI Company Profile
5.6.2 ADANI Mastography Product Specification
5.6.3 ADANI Mastography Production Capacity, Revenue, Price and Gross Margin
5.7 Allenger
5.7.1 Allenger Company Profile
5.7.2 Allenger Mastography Product Specification
5.7.3 Allenger Mastography Production Capacity, Revenue, Price and Gross Margin
5.8 AMICO JSC
5.8.1 AMICO JSC Company Profile
5.8.2 AMICO JSC Mastography Product Specification
5.8.3 AMICO JSC Mastography Production Capacity, Revenue, Price and Gross Margin
5.9 BMI Biomedical International
5.9.1 BMI Biomedical International Company Profile
5.9.2 BMI Biomedical International Mastography Product Specification
5.9.3 BMI Biomedical International Mastography Production Capacity, Revenue, Price and Gross Margin
5.10 Bracco
5.10.1 Bracco Company Profile
5.10.2 Bracco Mastography Product Specification
5.10.3 Bracco Mastography Production Capacity, Revenue, Price and Gross Margin
5.11 Carestream Health
5.11.1 Carestream Health Company Profile
5.11.2 Carestream Health Mastography Product Specification
5.11.3 Carestream Health Mastography Production Capacity, Revenue, Price and Gross Margin
5.12 EcoRay
5.12.1 EcoRay Company Profile
5.12.2 EcoRay Mastography Product Specification
5.12.3 EcoRay Mastography Production Capacity, Revenue, Price and Gross Margin
5.13 Fischer Medical Technologies
5.13.1 Fischer Medical Technologies Company Profile
5.13.2 Fischer Medical Technologies Mastography Product Specification
5.13.3 Fischer Medical Technologies Mastography Production Capacity, Revenue, Price and Gross Margin
5.14 Imaging Equipment
5.14.1 Imaging Equipment Company Profile
5.14.2 Imaging Equipment Mastography Product Specification
5.14.3 Imaging Equipment Mastography Production Capacity, Revenue, Price and Gross Margin
5.15 Internazionale Medico Scientifica
5.15.1 Internazionale Medico Scientifica Company Profile
5.15.2 Internazionale Medico Scientifica Mastography Product Specification
5.15.3 Internazionale Medico Scientifica Mastography Production Capacity, Revenue, Price and Gross Margin
5.16 ITALRAY
5.16.1 ITALRAY Company Profile
5.16.2 ITALRAY Mastography Product Specification
5.16.3 ITALRAY Mastography Production Capacity, Revenue, Price and Gross Margin
5.17 Metaltronica
5.17.1 Metaltronica Company Profile
5.17.2 Metaltronica Mastography Product Specification
5.17.3 Metaltronica Mastography Production Capacity, Revenue, Price and Gross Margin
5.18 MS Westfalia
5.18.1 MS Westfalia Company Profile
5.18.2 MS Westfalia Mastography Product Specification
5.18.3 MS Westfalia Mastography Production Capacity, Revenue, Price and Gross Margin
5.19 PerkinElmer
5.19.1 PerkinElmer Company Profile
5.19.2 PerkinElmer Mastography Product Specification
5.19.3 PerkinElmer Mastography Production Capacity, Revenue, Price and Gross Margin
5.20 Planmed
5.20.1 Planmed Company Profile
5.20.2 Planmed Mastography Product Specification
5.20.3 Planmed Mastography Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Mastography Market Size
6.2 North America Mastography Key Players in North America
6.3 North America Mastography Market Size by Type
6.4 North America Mastography Market Size by Application
7. East Asia
7.1 East Asia Mastography Market Size
7.2 East Asia Mastography Key Players in North America
7.3 East Asia Mastography Market Size by Type
7.4 East Asia Mastography Market Size by Application
8. Europe
8.1 Europe Mastography Market Size
8.2 Europe Mastography Key Players in North America
8.3 Europe Mastography Market Size by Type
8.4 Europe Mastography Market Size by Application
9. South Asia
9.1 South Asia Mastography Market Size
9.2 South Asia Mastography Key Players in North America
9.3 South Asia Mastography Market Size by Type
9.4 South Asia Mastography Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Mastography Market Size
10.2 Southeast Asia Mastography Key Players in North America
10.3 Southeast Asia Mastography Market Size by Type
10.4 Southeast Asia Mastography Market Size by Application
11. Middle East
11.1 Middle East Mastography Market Size
11.2 Middle East Mastography Key Players in North America
11.3 Middle East Mastography Market Size by Type
11.4 Middle East Mastography Market Size by Application
12. Africa
12.1 Africa Mastography Market Size
12.2 Africa Mastography Key Players in North America
12.3 Africa Mastography Market Size by Type
12.4 Africa Mastography Market Size by Application
13. Oceania
13.1 Oceania Mastography Market Size
13.2 Oceania Mastography Key Players in North America
13.3 Oceania Mastography Market Size by Type
13.4 Oceania Mastography Market Size by Application
14. South America
14.1 South America Mastography Market Size
14.2 South America Mastography Key Players in North America
14.3 South America Mastography Market Size by Type
14.4 South America Mastography Market Size by Application
15. Rest of the World
15.1 Rest of the World Mastography Market Size
15.2 Rest of the World Mastography Key Players in North America
15.3 Rest of the World Mastography Market Size by Type
15.4 Rest of the World Mastography Market Size by Application
16 Mastography Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter’s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
18.1 Research Methodology
18.1.1 Methodology/Research Approach
18.1.2 Data Source
18.2 Disclaimer
Market Segmentation
By Product Type
-
Liquid Fibrin Sealants: Primarily used for surface hemostasis and tissue sealing in general and specialized surgeries.
-
Fibrin Patches & Matrices: Collagen-based sponges impregnated with fibrinogen and thrombin, offering mechanical stability alongside biological sealing (e.g., TachoSil).
-
Autologous Fibrin Glue Kits: Systems that allow for the preparation of fibrin glue from the patient’s own blood, minimizing the risk of viral transmission or immunological reactions.
By Clinical Application
-
Cardiovascular Surgery: Suture line reinforcement and prevention of air leaks or bleeding in vascular grafts.
-
Neurosurgery: Dural sealing to prevent cerebrospinal fluid (CSF) leaks.
-
Orthopedic Surgery: Management of bleeding in total joint replacements and spinal fusions.
-
General Surgery: Spleen and liver trauma, as well as gastrointestinal anastomoses.
-
Wound Management: Treatment of chronic ulcers and burn grafts.
By End-User
-
Hospitals & Tertiary Care Centers: The primary volume drivers for high-stakes surgical procedures.
-
Ambulatory Surgical Centers (ASCs): A rapidly expanding segment due to the rise of minimally invasive outpatient surgeries.
-
Specialty Clinics: Focusing on plastic surgery and dental applications.
Regional Analysis
-
North America: Leads the market value due to advanced healthcare infrastructure, high surgical volumes, and the early adoption of high-cost biosurgical products in the United States and Canada.
-
Europe: A mature market driven by rigorous safety standards and a strong presence of key players in Germany, Switzerland, and the UK. Emphasis is placed on standardized clinical guidelines for blood-saving techniques.
-
Asia-Pacific: Anticipated to be the fastest-growing region. Growth is propelled by an aging population in Japan and China, a surge in medical tourism in Southeast Asia, and improving healthcare accessibility in India.
-
LAMEA (Latin America, Middle East, & Africa): Growth is emerging from the modernization of surgical suites in the GCC countries and the expansion of private healthcare networks in Brazil and Mexico.
Top Key Players
The landscape is dominated by diversified pharmaceutical giants and specialized biotechnology firms:
-
Baxter International Inc. (Tisseel, Artiss)
-
Ethicon, Inc. (Johnson & Johnson) (Evicel, Evarrest)
-
CSL Behring (CSL Limited)
-
Takeda Pharmaceutical Company Limited (TachoSil)
-
Mallinckrodt PLC
-
Vivostat A/S (Leader in autologous systems)
-
Regen Lab SA
-
Harvest Technologies (Terumo BCT)
-
Shanghai RAAS Blood Products Co., Ltd.
-
Kaketsuken (KM Biologics)
-
LifeBond Ltd.
-
Pharming Group N.V.
-
STB Lifesaving Technologies
-
Tissuemed Ltd.
